At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 193 enrolled
Drug / intervention
Tropifexor (LJN452) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of a Combination Treatment of Tropifexor (LJN452) and Cenicriviroc (CVC) in Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis
In Brief
A Phase 2 clinical trial evaluating Tropifexor (LJN452) and Cenicriviroc (CVC) for Non-alcoholic Steatohepatitis (NASH). Completed, enrolled 193 participants across 65 sites in 17 countries.
Detailed Summary
The purpose of this study was to assess the safety, tolerability, and efficacy of a combination treatment of tropifexor (LJN452) and cenicriviroc (CVC) in adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-alcoholic Steatohepatitis (NASH)
CountriesArgentina, Belgium, Canada, Czechia, Egypt, France, Germany, India, Israel, Italy, Latvia, Russia, Singapore, Spain, Turkey (Türkiye), United Kingdom, United States
CollaboratorsAllergan
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMay 2018
Enrollment StartSep 2018
Primary CompletionSep 2020
Study CompletionOct 2020
TodayJul 2026
First PostedMay 7, 2018
Enrollment StartSep 11, 2018
Primary CompletionSep 15, 2020
Study CompletionOct 15, 2020
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 8.2 years ago
Interventions
Tropifexor (LJN452)drug
Comparison with monotherapy and different combination doses
Cenicriviroc (CVC)drug
Comparison with monotherapy and different combination doses